19 Oct
2021
14:19 E.S.T.

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021

Read more

12 Oct
2021
14:53 E.S.T.

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Read more

26 Aug
2021
14:38 E.S.T.

Cellectis Announces Participation in Five Investor Conferences

Read more

05 Aug
2021
14:43 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

Read more

29 Jul
2021
16:06 E.S.T.

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

Read more

14 Jun
2021
14:11 E.S.T.

Cellectis’ Innovation Days event highlighted New Product Development,  New Genome Surgery Platform .HEAL, and Manufacturing Capabilities

Read more

02 Jun
2021
02:35 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021

Read more

11 May
2021
13:05 E.S.T.

Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

Read more

06 May
2021
14:28 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021

Read more

26 Apr
2021
15:06 E.S.T.

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021

Read more